Lenoss Medical tops 500 OsteoPearl procedures
Lenoss Medical said its OsteoPearl biological allograft implant has surpassed 500 procedures, with more than half completed in the last 12 months. The milestone signals growing use of a non-PMMA option for vertebral compression fracture repair as hospitals and physicians expand adoption.
Why it matters: - Lenoss Medical's milestone suggests broader clinical uptake for a biological alternative in vertebral compression fracture repair. - OsteoPearl® is positioned as an option for osteoporotic spinal fractures where PMMA bone cement has been the standard approach. - More than half of the 500-plus procedures happened in the last 12 months, pointing to accelerating use.
What happened: - Lenoss Medical said OsteoPearl® surpassed 500 procedures. - The company is based in Providence, Rhode Island. - The milestone was announced Sept. 22, 2026. - The company linked to a one-minute video for more information on its mission and progress.
The details: - OsteoPearl® is a biological allograft implant made from 100% cortical bone. - The implant provides a scaffold for ongrowth and/or ingrowth of newly formed bone. - Lenoss Medical describes OsteoPearl® as an alternative to PMMA bone cement. - The company focuses on repairing osteoporotic spinal fractures. - Lenoss Medical's flagship product is the OsteoPearl® Biological Allograft. - The company says the implant is designed to provide natural bone where more bone is needed most.
Between the lines: - CEO and Founder Dom Messerli said adoption has expanded across more hospitals and physicians over the past year. - That growth matters because medical-device adoption often depends on surgeon familiarity, hospital purchasing and clinical confidence. - A biological implant category could appeal to clinicians looking for a non-cement approach in VCF repair.
What's next: - Lenoss Medical is likely to keep pushing adoption with hospitals and physicians. - The company will need continued procedural growth to show the milestone is part of a durable trend. - Further clinical and market traction will determine whether OsteoPearl® becomes a broader standard option in this segment.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Health Industry Watch
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.